Guardant Health (NASDAQ:GH) Price Target Raised to $195.00 at JPMorgan Chase & Co.

Guardant Health (NASDAQ:GH) had its price objective raised by analysts at JPMorgan Chase & Co. from $185.00 to $195.00 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective would suggest a potential upside of 21.40% from the company’s current price.

Other analysts also recently issued reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Guardant Health in a report on Friday, July 17th. BTIG Research upped their target price on Guardant Health from $190.00 to $195.00 and gave the company a “buy” rating in a research report on Friday. Guggenheim raised their target price on Guardant Health from $160.00 to $190.00 and gave the stock a “buy” rating in a research note on Thursday, July 16th. Canaccord Genuity Group lifted their target price on Guardant Health from $135.00 to $205.00 and gave the stock a “buy” rating in a report on Tuesday, July 14th. Finally, Morgan Stanley boosted their price target on Guardant Health from $130.00 to $175.00 and gave the company an “overweight” rating in a research note on Thursday, July 9th. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $179.82.

Guardant Health Price Performance

Shares of GH traded up $8.27 during trading hours on Friday, hitting $160.62. 2,738,855 shares of the stock were exchanged, compared to its average volume of 2,312,133. Guardant Health has a fifty-two week low of $40.35 and a fifty-two week high of $176.58. The business has a 50-day moving average of $142.58 and a 200-day moving average of $113.03. The firm has a market capitalization of $21.30 billion, a P/E ratio of -47.43 and a beta of 1.59.

Insider Activity at Guardant Health

In related news, insider Chris Freeman sold 24,406 shares of the company’s stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $118.67, for a total transaction of $2,896,260.02. Following the transaction, the insider directly owned 60,034 shares of the company’s stock, valued at approximately $7,124,234.78. This represents a 28.90% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Meghan V. Joyce sold 10,000 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $126.98, for a total value of $1,269,800.00. Following the completion of the transaction, the director owned 11,183 shares in the company, valued at approximately $1,420,017.34. The trade was a 47.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 708,565 shares of company stock worth $90,556,597. 5.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Guardant Health

Hedge funds and other institutional investors have recently modified their holdings of the company. Handelsbanken Fonder AB raised its position in shares of Guardant Health by 159.9% during the second quarter. Handelsbanken Fonder AB now owns 301,041 shares of the company’s stock worth $45,165,000 after purchasing an additional 185,200 shares during the period. Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new stake in Guardant Health in the 2nd quarter valued at $213,000. Allied Private Wealth LLC acquired a new stake in Guardant Health in the 2nd quarter valued at $72,000. MRA Advisory Group increased its stake in Guardant Health by 6.2% during the 2nd quarter. MRA Advisory Group now owns 12,026 shares of the company’s stock valued at $1,804,000 after purchasing an additional 706 shares in the last quarter. Finally, GAMMA Investing LLC increased its stake in Guardant Health by 14.5% during the 2nd quarter. GAMMA Investing LLC now owns 965 shares of the company’s stock valued at $145,000 after purchasing an additional 122 shares in the last quarter. Institutional investors own 92.60% of the company’s stock.

More Guardant Health News

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Guardant reported second-quarter revenue of $335.0 million, up 44% year over year and above the roughly $314 million consensus estimate. Oncology revenue rose 38% to $219.1 million, while oncology testing volume increased 63% to approximately 104,000 tests. Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
• Positive Sentiment: The company increased its 2026 revenue guidance to a range of $1.3 billion to $1.4 billion, supporting expectations for continued demand for its cancer screening and diagnostic tests. Guardant Health Raises 2026 Revenue Outlook
• Positive Sentiment: Guardant’s adjusted quarterly loss narrowed from the prior-year period, and its reported loss of $0.42 per share was substantially better than the $0.76 consensus estimate cited by MarketBeat. Guardant Health Second-Quarter Earnings Results
• Neutral Sentiment: Management’s earnings call and presentation emphasized rapid test-volume expansion and the company’s commercial growth strategy, but investors will likely focus on whether that growth can translate into sustainable profitability. Guardant Health 2026 Second-Quarter Results Presentation
• Negative Sentiment: Guardant remains unprofitable, with a quarterly loss, and the deeper-loss aspect of the results could temper enthusiasm if expenses continue to rise faster than revenue. The company’s valuation therefore depends heavily on maintaining high growth and improving operating leverage. Does Guardant’s Surging Revenue and Deeper Losses Reframe the Growth Thesis for GH?

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.